Biowell Labs Global score history
Every recorded change to Biowell Labs Global’s overall score since November 19, 2026, with the audit note written at the time. Scores follow our published methodology; affiliate status never affects them.
- Score today
- 2.55/10
Score today
- Score changes
- 2
Score changes
- Audit entries
- 3
Audit entries
Score over time
Every entry newest first
- Lowered from2.60to2.55(-0.05)
Market prices recalculated on 20 November 2026 after Peptide Privé and VialBench Research were added pricing 8.3 to 8.0.
- Raised from2.55to2.60(+0.05)
Market prices recalculated on 20 November 2026 after Optima Supply was added pricing 8.0 to 8.3.
- First publishedat2.55
First audit after the vendor's submission: 21 catalogue products listed (tesamorelin out of stock); 3 (BPC-157, MOTS-c, retatrutide) have a certificate, each issued by BioWell America LLC itself on 2026-11-16 reproducing an unnamed manufacturer's batch results, naming no laboratory and no key (flat 2.0, A3); 18 have none; CLAIM -0.1 (product pages 'Every batch is independently tested' vs certificates 'The analysis was performed by the manufacturer'); lab 0.3, shipping 4.0 (no returns for research products, damaged items case by case, no dispatch time, B7 -0.5 for different shipping rates in the terms and the shipping policy), pricing 8.0 (r 0.863 over 21 products, regular prices), operating history 2.2 (domain 2025-09-28), transparency 5.5 (entity, virtual-office address, phone, owner named on the certificates; terms name no governing law; no laboratory named); testing gate not met (0 of 21). Overall 2.55.
Score changes for every vendor are on the score changes page. Biowell Labs Global may display its current score with the score badge, which updates automatically and has no effect on the score.